Evidence map›Paper›PMID 38461512›Full record

ArticleJournal of Huntington's disease2024

Alterations in Cerebrospinal Fluid Urea Occur in Late Manifest Huntington's Disease.

Anna C Pfalzer, Shuhei Shiino, James Silverman, Simona G Codreanu, Stacy D Sherrod, John A McLean, Daniel O Claassen

Open access · greenAbstract read
In one paragraph

Article in Journal of Huntington's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Anna C PfalzerDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
Shuhei ShiinoDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
James SilvermanDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
Simona G CodreanuDepartment of Chemistry and Center for Innovative Technology, Vanderbilt University, Nashville, TN, USA.
Stacy D SherrodDepartment of Chemistry and Center for Innovative Technology, Vanderbilt University, Nashville, TN, USA.
John A McLeanDepartment of Chemistry and Center for Innovative Technology, Vanderbilt University, Nashville, TN, USA.
Daniel O ClaassenDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
Vanderbilt University Medical Center · USVirginia Innovation Partnership Corporation · USVanderbilt University · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3M
Understanding metabolic changes associated with chronic manganese exposure and Alzheimer's DiseaseR03NS125243 · NINDS · VANDERBILT UNIVERSITY · PI HARRISON, FIONA EDITH, SHERROD, STACY D. · 2022 to 2022
$177k
Medical Research CouncilNCATS NIH HHS UL1 TR002243NICHD NIH HHS P50 HD103537NINDS NIH HHS R03 NS125243
6 · The paper itself

Abstract

Background: Huntington's disease (HD) is a neurodegenerative disorder caused by expanded cytosine-adenine-guanine (CAG) repeats in the Huntingtin gene, resulting in the production of mutant huntingtin proteins (mHTT). Previous research has identified urea as a key metabolite elevated in HD animal models and postmortem tissues of HD patients. However, the relationship between disease course and urea elevations, along with the molecular mechanisms responsible for these disturbances remain unknown. Objective: To better understand the molecular disturbances and timing of urea cycle metabolism across different stages in HD. Methods: We completed a global metabolomic profile of cerebrospinal fluid (CSF) from individuals who were at several stages of disease: pre-manifest (PRE), manifest (MAN), and late manifest (LATE) HD participants, and compared to controls. Results: Approximately 500 metabolites were significantly altered in PRE participants compared to controls, although no significant differences in CSF urea or urea metabolites were observed. CSF urea was significantly elevated in LATE participants only. There were no changes in the urea metabolites citrulline, ornithine, and arginine. Conclusions: Overall, our study confirms that CSF elevations occur late in the HD course, and these changes may reflect accumulating deficits in cellular energy metabolism.

Indexed as

Huntington DiseaseAnimalsDisease ProgressionHumansHuntingtin ProteinUreaHuntingtin ProteinUreacerebrospinal fluidHuntington’s diseasemetabolismneurodegenerationurea

Identifiers

PMID38461512
PMCPMC11238568
OpenAlexW4392454301

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.